@‘Sl“Iˆã—ÊJ”­ŠwuÀ@—Տ°ŒŸ¸ˆãŠw•ª–ì

@@@ Department of Laboratory Medicine

@‘åŠw‰@“üŠw‚ðl‚¦‚Ä‚¢‚é•û‚Ö

 

y“–Œ¤‹†Žº‚ÌŒ¤‹†ƒe[ƒ}z

 

ƒe[ƒ} 1F@”’ŒŒ•aEƒŠƒ“ƒpŽî×–E‚ُ̈푝B‚̍זE•ªŽq¶•¨Šw“IƒƒJƒjƒYƒ€‚̉𖾁B“Á‚ɁA‹}«”’ŒŒ•aŠ²×–E‚̐§ŒäƒVƒOƒiƒ‹‚̉ð–¾

@@@@@

@@ˆÓ‹`:@’P‚ɁAŽ¾Š³–¼‚â•aŒ^‚̐f’f‚ð‚·‚é‚Ì‚Å‚Í‚È‚­AŠeÇ—Ⴒ‚Æ‚Ì”­Ç‚⑝B‚ÌŒ®‚ƂȂ镪Žq•a‘Ԃ𖾂炩‚É‚·‚éŒÂ«f’f–@‚ðŠJ”­‚·‚éB

@@@@@@@@@@ ”’ŒŒ•a×–E‘S‘Ì‚Å‚Í‚È‚­A”’ŒŒ•aŠ²×–E‚ðŽ¡—Ã•W“I‚Æ‚·‚邱‚ƂŁAŽîᇂ̗}§‚Å‚Í‚È‚­Aªâ‚ð–ÚŽw‚·Ž¡—ÂɌq‚ªé•ªŽq•a‘Ô‚ð‰ð–¾‚·‚éB

 

ƒe[ƒ} 2F@ã‹L‚Ì•ªŽqƒƒJƒjƒYƒ€‚ɑ΂·‚éV‹K•ªŽq•W“I–ò‚Ì’Tõ‚ƁA—LŒø«‚ð—\‘ª‚·‚é–òÜŠ´Žó«ŒŸ¸–@‚ÌŠJ”­

 

@@ˆÓ‹`F ]—ˆŒ^‚̍R‚ª‚ñÜ‚͐³í×–E‚ðŠª‚«ž‚ñ‚ōזE‚ð‰ó‚µ‚Ä‚µ‚Ü‚¤‚½‚߁AŽîᇍזE‚¾‚¯‚ð‰ó‚·•ªŽq•W“I–ò‚ª–]‚Ü‚ê‚éB

@@@@@ Œ»ÝAŽíX‚Ì•ªŽq•W“I–ò‚ª—Տ°‰ž—p‚³‚ê‚Ä‚¢‚邪A—LŒø«‚ð—\‘ª‚·‚錟¸‚͏\•ª‚ɂ͐®‚Á‚Ä‚¢‚È‚¢‚½‚߁A‚»‚ê‚ðŠJ”­‚·‚éB

@@@@@ ‚³‚ç‚ɁA»–òŠé‹Æ‚âŠCŠOŒ¤‹†Ž{Ý‚Ì‘n–òŒ¤‹†ŽÒ‚Æ‹¤“¯‚ŁAV‚½‚È•ªŽq•W“I–ò‚Ì•W“I‚ƂȂ镪Žq‚ð’Tõ‚·‚éB

 

ƒe[ƒ}3F@Žîᇂ̐V‚½‚Ȉâ“`ŽqŒŸ¸–@‚â”÷—ÊŽc‘¶ŽîᇍזE‚ÌŒŸo–@‚ÌŠJ”­

@@@@@

@@ˆÓ‹`: ‹ß”NAŒ¤‹†ŽºƒŒƒxƒ‹‚ÅŽîᇂ̗lX‚Ȉâ“`ŽqˆÙí‚ªŒ©‚¢o‚³‚ê‚Ä‚¢‚邪A—Տ°Œ»ê‚ʼnž—p‚Å‚«‚é‚悤‚Ȋȕւō‚Š´“x‚Ȉâ“`ŽqŒŸ¸–@‚ðŠJ”­‚·‚éB

@@@@@@@@@ ŽîᇍזE‚©‚ç—Vo‚µ‚ÄŒŒ‰t’†‚𗬂ê‚éˆâ“`Žq’f•Ð‚ðŒŸo‚·‚éAŠ³ŽÒ‚³‚ñ‚ւ̐¶ŒŸ‚̐NP‚ð—v‚³‚È‚¢ˆâ“`ŽqŒŸ¸–@‚ðŠJ”­‚·‚éB

@@@@@iÅ‹ßA‚±‚ÌŽè–@‚́uƒŠƒLƒbƒhƒoƒCƒIƒvƒV[v‚Æ‚µ‚Đ¢ŠE‚Řb‘è‚É‚È‚Á‚Ä‚¢‚Ü‚·‚ªA“–ƒ‰ƒ{‚Å‚Í17”N‘O‚©‚çŽÀŽ{‚µ‚Ä‚¢‚Ü‚·j

 

‚±‚Ì‚Ù‚©AŒŸ¸•”×‹ÛŒŸ¸Žº‚ŁA‰@“àŠ´õŠÄŽ‹‚Ì‚½‚߂̍׋ۂ̈â“`ŽqŒ^‰ðÍ‚⓯’è‚ÌŒŸ¸–@‚ðŠJ”­‚µ‚Ä‚¢‚Ü‚·B

 

ˆêlˆêl‚ª“Æ—§‚µ‚½ƒe[ƒ}‚ÅŒ¤‹†‚ð‚µ‚Ä‚¢‚Ü‚·B@¨ ƒe[ƒ}‚ªŒ©‚‚©‚ç‚È‚¯‚ê‚Î’ñ‹Ÿ‚µ‚Ü‚·B

•¡”‚̃e[ƒ}‚ð•Às‚µ‚čs‚¤‚±‚Æ‚à‰Â”\‚Å‚·B@@¨ Œ¤‹†‚Ì•‚ðŠg‚°‚邽‚߁A‚¨‚æ‚сAˆê‚‚ª‚¤‚Ü‚­‚¢‚©‚È‚©‚Á‚½Žž‚Ì”õ‚¦‚Æ‚µ‚āB

Eê‚ÌðŒ‚ª‹–‚¹‚΁AŽÐ‰ïl‘åŠw‰@¶‚à‰Â”\‚Å‚·B¨ “­‚«‚È‚ª‚çŠwˆÊŽæ“¾‚à–ÚŽw‚·ƒVƒXƒeƒ€‚Å‚·B

 

y“–Œ¤‹†Žº‚ŏC“¾‚Å‚«‚錤‹†Žè–@z

 

‘åŠw‰@¶‚ªC“¾‚·‚錤‹†Žè–@‚Æ‚µ‚āA×–E”|—{A×–EŒ`‘ÔŠÏŽ@Aƒtƒ[ƒTƒCƒgƒƒgƒŠ[‰ðÍAPCR‚ð—p‚¢‚½DNA•ÏˆÙ‰ðÍA’è—ÊRT-PCRAƒCƒ€ƒmƒuƒƒbƒg‰ðÍ‚È‚Ç‚ðs‚¤B

 

•K—v‚ɉž‚¶‚āAƒRƒƒj[ƒAƒbƒZƒCAŒuŒõŒ°”÷‹¾‚É‚æ‚é×–E“à’`”’‰ðÍAƒV[ƒNƒGƒ“ƒX‰ðÍAsiRNA“±“üiƒGƒŒƒNƒgƒƒ|ƒŒ[ƒVƒ‡ƒ“–@jAƒ}ƒCƒNƒƒAƒŒƒC‚É‚æ‚é–Ô—…“Iˆâ“`Žq”­Œ»‰ðÍAŽŸ¢‘ãƒV[ƒNƒGƒ“ƒT[‚É‚æ‚éƒGƒNƒ\[ƒ€‰ðÍ‚âRNA-seq‰ðÍ‚ðs‚¤B

 

‚±‚ê‚ç‚̐ݔõ‚̓‰ƒ{“à‚ɐ®‚Á‚Ä‚¢‚邪Aƒ}ƒCƒNƒƒAƒŒƒC‰ðÍ‚ÆŽŸ¢‘ãƒV[ƒNƒGƒ“ƒT[‚Í‹¤“¯Œ¤‹†Ž{Ý‚âŠO•”ˆÏ‘õ‚ōs‚¤B

 

ŽÀŒ±‚ÌŒoŒ±‚ª‘S‚­‚È‚­‚Ä‚à–â‘è‚Í‚ ‚è‚Ü‚¹‚ñB‘åŠw‰@“üŠw‘O‚ÍŒoŒ±‚ª‚È‚¢‚Ì‚ª•’Ê‚Å‚·B“–ƒ‰ƒ{‚ÅŽè‹Z‚ðŽw“±‚µ‚Ü‚·B

 

y‘åŠw‰@¶‚Ì–Ú•Wz

@

1jŽÀŒ±‚⌤‹†¶Šˆ‚ðŠy‚µ‚Þ‚±‚Æ‚ª‚Å‚«AV‚½‚È”­Œ©‚ÉŠì‚Ñ‚ðŠ´‚¶‚邱‚Æ‚ª‚Å‚«‚éƒTƒCƒGƒ“ƒeƒBƒXƒg‚É‚È‚éB

@i«—ˆAŒ¤‹†ŽÒ‚É‚È‚ç‚È‚¢‚Æ‚µ‚Ä‚àA‚»‚ꂼ‚ê‚ÌŽdŽ–‚ŁA‰ÈŠw“I‚ÈŽvl—Í‚â”»’f—Í‚ª–ð‚É—§‚¿‚Ü‚·j

 

2j•M“ª‰‰ŽÒ‚Æ‚µ‚č‘“àŠw‰ï‚ÅŒ¤‹†¬‰Ê‚ð”­•\‚·‚éB

@ Šwp“I‚ɈӋ`[‚¢¬‰Ê‚ª“¾‚ç‚ꂽê‡‚́i‚Æ‚¢‚¤‚©A‰‰‘肪ƒAƒNƒZƒvƒg‚³‚ꂽ‚çj‘ÛŠw‰ï‚Å”­•\‚·‚éB

@i—·”ï‚Í‹³Žº‚Å•‰’S‚µ‚Ä‚¢‚Ü‚·j

 

3j‚±‚ê‚ç‚̐¬‰Ê‚́A•M“ª’˜ŽÒ‚Æ‚µ‚āA‰p•¶Œ´’˜˜_•¶‚É‚·‚éB

@i‹³ˆõ‚ª˜_•¶ì¬‚̃Tƒ|[ƒg‚ð‚µ‚Ü‚·j

 

y“–Œ¤‹†Žº‚Ì“ú‰Ûz

@

‘Sˆõ‚ōs‚¤Œ¤‹†”­•\ƒ~[ƒeƒBƒ“ƒOAŠw‰ï—\‰‰‰ï‚âŽG—p‚ÌŽžŠÔˆÈŠO‚ɂ́A“Á‚ÉŒˆ‚Ü‚è‚Í‚È‚­AD‚«‚ÈŽž‚É—ˆ‚ÄŽÀŒ±‚ðŠJŽn‚µAI—¹‚µ‚ÄŒ‹\‚Å‚·B

ŠwŠO‚ł̃Aƒ‹ƒoƒCƒg‚à‰Â”\‚Å‚·BŠó–]‚ª‚ ‚ê‚΁AƒeƒB[ƒ`ƒ“ƒOEƒAƒVƒXƒ^ƒ“ƒgi—L‹‹j‚Æ‚µ‚āAˆãŠw‰ÈŽÀK‚ÌŽè“`‚¢‚ðs‚¢‚Ü‚·B

 

y˜A—æz

 

“Œ“ci‚Æ‚¤‚¾j@tohda.mlab@tmd.ac.jp@@ 03-5803-5334i’¼’ʁj

 

Œ¤‹†ƒe[ƒ}‚́AŽîᇂ̑B‹@˜‚̉𖾂₻‚Ì•ªŽq•W“IŽ¡—Öò‚ÌŠ´Žó«ŽŽŒ±AV‚½‚Ȉâ“`ŽqŒŸ¸–@‚ÌŠJ”­‚È‚Ç‚ª’†S‚Æ‚È‚è‚Ü‚·‚ªAŠeŽ©‚ÌŠó–]‚⏫—ˆ‚̐i˜H‚ÉŠî‚¢‚Ä‘Š’k‚̏ãA‰Â”\‚ÈŒÀ‚艞‚¶‚é‚悤‚É‚µ‚Ü‚·B‚È‚¨Aó‹µ‚̕ω»‚É‚æ‚èA“K‹XA•ÏX‚·‚邱‚Æ‚Í‚ ‚è‚Ü‚·B«—ˆAŒ¤‹†ŽÒ‚¾‚¯‚Å‚È‚­A—Տ°ˆã‚⌟¸‹ZŽt‚ð–ÚŽw‚µ‚Ä‚¢‚éŠw¶‚³‚ñ‚àŠ½Œ}’v‚µ‚Ü‚·BˆãŠw‰ÈˆÈŠO‚Ì•û‚àŠ½Œ}‚µ‚Ü‚·iŒ»Ý‚àŠˆ–ô’†‚Å‚·jB

 

ƒ‰ƒ{‚ÌŒ©Šw‚àŽžAŽó‚¯•t‚¯‚Ä‚¢‚Ü‚·Bƒ[ƒ‹‚ȂǂŁA‰“—¶‚È‚­‚¨‹CŒy‚É‚²˜A—‚­‚¾‚³‚¢B

 

------------------------------------------------------------------------------------------------------------------

 

y‚±‚ê‚Ü‚Å‚ÌŽå‚ÈŒ¤‹†¬‰Êz

 

i‚Pj”’ŒŒ•a×–E‚Ì‘B‹@˜‚Ì“Á«‚𖾂炩‚É‚·‚錟¸–@A‚»‚ê‚ɑ΂·‚镪Žq•W“IŽ¡—Öò‚ÌŠ´Žó«ŒŸ¸–@‚ÌŠJ”­

 

@”’ŒŒ•a‚́A”’ŒŒ•a×–E‚Ì–³§ŒÀ‚Ì‘B‚Ɛ³í‘¢ŒŒ‹@\‚̏áŠQ‚É‚æ‚èA‚»‚Ì•a‘Ô‚ªŒ`¬‚³‚ê‚éB”’ŒŒ•a×–E‚Ì‘B‚́A‚»‚̍זEW’c‚Ì’†‚Ì‚²‚­­”‚Ì”’ŒŒ•aŠ²×–E‚É‚æ‚Á‚Ĉێ‚³‚ê‚Ä‚¢‚éBŽ„‚½‚¿‚́A”’ŒŒ•aŠ²×–E‚̐§ŒäƒƒJƒjƒYƒ€‚ð×–EE•ªŽqƒŒƒxƒ‹‚Å–¾‚ç‚©‚É‚·‚邱‚Æ‚É‚æ‚èAŠ³ŽÒ‚³‚ñ‚²‚Æ‚Ì”’ŒŒ•aŠ²×–E‚Ì“Á’¥‚𖾂炩‚É‚·‚錟¸–@‚ƁA‚»‚Ì•ªŽq•a‘Ԃɉž‚¶‚½Ž¡—Ö@A‚¨‚æ‚сA‚»‚ÌŽ¡—ÃŒø‰Ê‚ð—\‘ª‚·‚錟¸–@‚ðŠJ”­‚·‚邱‚Æ‚ð–ÚŽw‚µ‚Ä‚¢‚éB

:mlab_graduate-school.files:image001.jpg

 

 

@‚í‚ê‚í‚ê‚́A”’ŒŒ•aŠ²×–E‚Ì‘B‹@\‚ðƒTƒCƒgƒJƒCƒ“‚̍ì—p‚Æ‚¢‚¤ŠÏ“_‚©‚猤‹†‚𑱂¯‚Ä‚«‚½B‹ï‘Ì“I‚ɂ́AƒTƒCƒgƒJƒCƒ“‚Ì”’ŒŒ•a×–E”|—{Œn‚É‚¨‚¯‚鎩ŒÈ•¡»”\‚╪‰»‘B”\‚ւ̍ì—pA”’ŒŒ•a×–E‚É”­Œ»‚·‚éƒTƒCƒgƒJƒCƒ“‚âƒTƒCƒgƒJƒCƒ“Žó—e‘̂̉ðÍAƒTƒCƒgƒJƒCƒ“Žó—e‘̂̃VƒOƒiƒ‹“`’BŒn‚̉ðÍ‚È‚Ç‚Å‚ ‚éB

 

@Œ»Ý‚Í‘¢ŒŒŠ²×–E‚ÌŽ©ŒÈ•¡»‚ɏd—v‚È–ðŠ„‚ðŽ‚ÂNotchƒVƒOƒiƒ‹‚́A”’ŒŒ•a×–E‚Ì‘B‚É‚¨‚¯‚é–ðŠ„‚ÉÅ“_‚ð“–‚Ä‚ÄŒ¤‹†‚µ‚Ä‚¢‚éBNotch‚Ƃ́A‘¢ŒŒŠ²×–E•\–Ê‚É”­Œ»µ‚Ä‚¢‚é’`”’‚Å‚ ‚éB‚í‚ê‚í‚ê‚͐¢ŠE‚ɐæ‹ì‚¯‚āAŠ³ŽÒ”’ŒŒ•a×–E‚ÉNotch’`”’‚âNotchƒŠƒKƒ“ƒh’`”’‚ª”­Œ»‚µ‚Ä‚¢‚邱‚Æ‚ð•ñ‚µANotchƒŠƒKƒ“ƒh”½‰ž«‚̃qƒg×–EŠ”‚ðŽ÷—§‚µ‚½B‚³‚ç‚É“–Œ¤‹†Žº‚Ì‘åŠw‰@¶‚炪A”’ŒŒ•a×–E‚Ì‘B‚╪‰»‚ɑ΂·‚éNotchƒŠƒKƒ“ƒh’`”’‚âNotch‘jŠQ–ò‚̍ì—p‚â‚»‚Ì•ªŽq‹@˜‚ÉŠÖ‚·‚é‹»–¡[‚¢”­Œ©‚ð‚µA•ñ‚µ‚Ä‚«‚½BNotchƒVƒOƒiƒ‹‚̐§Œä‚́AÄ¶ˆã—Â┒ŒŒ•a‚ɑ΂·‚镪Žq•W“IŽ¡—Âւ̉ž—p‚ªŠú‘Ò‚³‚ê‚Ä‚¨‚èA—Տ°‰ž—p‚ÉŒü‚¯‚āA‘“àŒ¤‹†‹@ŠÖ‚âŠé‹ÆŒ¤‹†•”–å‚Æ‚Ì‹¤“¯Œ¤‹†‚ài‚ß‚Ä‚¢‚éBÅ‹ß‚́ANotchƒVƒOƒiƒ‹‚Æ“¯—l‚ÉŠ²×–E‚̐§Œä‚ɏd—v‚ÈWntƒVƒOƒiƒ‹AHedgehogƒVƒOƒiƒ‹AmTORƒVƒOƒiƒ‹AHIFƒVƒOƒiƒ‹‚Ȃǂɂ‚¢‚Ä‚àŒ¤‹†‚µ‚Ä‚¢‚éB

mlab_graduate-school.files/image003.gif

@

 

m“–Œ¤‹†Žº‚ōs‚È‚í‚ꂽAã‹L‚ÉŠÖ‚·‚éÅ‹ß‚̘_•¶n–ˆó@‘åŠw‰@¶(‚à‚µ‚­‚͈ãŠw•”Šw¶)‚ª•M“ª’˜ŽÒ‚̘_•¶

@ Hypoxia up-regulates HIF expression while suppressing cell growth and NOTCH activity in leukaemia cells

–NOTCH activation promotes glycosyltransferase expression in human myeloid leukemia cells@

@ FOXP3 knockdown inhibits the proliferation and reduces NOTCH1 expression of T cell acute lymphoblastic leukemia cells

–Effects of MERTK inhibitors UNC569 and UNC1062 on the growth of acute myeloid leukaemia cells.

–MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells.

–BMI1 Inhibitors Downregulate NOTCH Signalling and Suppress Proliferation of Acute Leukemia Cells.

–Effect of EPH-ephrin signaling on the growth of human leukemia cells.

–NOTCH Knockdown Affects the Proliferation and mTOR Signaling of Leukemia Cells.

–Effects of the HIF1 Inhibitor, Echinomycin, on Growth and NOTCH Signalling in Leukaemia.

–Comparative effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in leukemia cells.

–Effect of BMP4 on the growth and clonogenicity of human leukemia and lymphoma cells.

–Flow cytometric analysis of Notch1 and Jagged1 expression in normal blood cells and leukemia cells.

–Promotion of the Self-renewal Capacity of Human Leukemia Cells by Sonic Hedgehog Protein.

–Effects of Combination of Notch Inhibitor plus Hedgehog Inhibitor or Wnt Inhibitor on Growth of Leukemia Cells.

–Gamma-secretase inhibitors induce erythroid differentiation in erythroid leukemia cell lines.

–Effects of g-secretase inhibitors on the growth of leukemia cells.

–Cyclopamine and quercetin suppress the growth of leukemia and lymphoma cells.

–Transition of cleaved Notch1 and gene expression changes in myeloblastic leukemia cells stimulated with Notch ligands.

@ NFkB activation induced by Notch ligand stimulation in acute myeloid leukemia cells.

–Promotion of the self-renewal capacity of human acute leukemia cells by Wnt3A.

–Involvement of Notch signaling in myelodysplastic syndrome.

–g-secretase inhibitors suppress the growth of leukemia and lymphoma cells.

 

i‚QjŽîᇂ̐V‚½‚Ȉâ“`ŽqŒŸ¸–@A”÷—ÊŽc‘¶ŽîᇍזE‚ÌŒŸo–@‚ÌŠJ”­

 

@ŠàŽ¡—Â̖ڕW‚́AŽîᇍזE‚ðªâ‚µŠ³ŽÒ‚ðŽ¡–ü‚É“±‚­‚±‚Æ‚É‚ ‚éBŽíX‚Ì—LŒø‚ÈŽ¡—Â̌ã‚É‚àA”÷—ÊŽîᇍזE‚ÌŽc‘¶‚âÄ”­‚Ì–â‘肪Žc‚³‚ê‚Ä‚¢‚éB‚±‚Ì”÷—ÊŽîᇍזE‚ÌŒŸo‚́A’ljÁŽ¡—Â̕K—v«‚Ì”»’f‚âAÄ”­‚Ì‘Šú”­Œ©‚É—L—p‚Å‚ ‚éB‚í‚ê‚í‚ê‚͈â“`ŽqŒŸ¸‚ð—p‚¢‚āA”÷—ÊŽîᇍזE‚ð“KŠi‚ÉŒŸo‚·‚錟¸–@‚ÌŠJ”­‚ÉŽæ‚è‘g‚ñ‚Å‚¢‚éB

m“–Œ¤‹†Žº‚̏ã‹L‚ÉŠÖ‚·‚éÅ‹ß‚̘_•¶n

–Detection of the MYD88 mutation by the combination of the allele-specific PCR and quenching probe methods.

@ Establishment of a quenching probe method for detection of NPM1 mutations in acute myeloid leukemia cells.

–Advantages of the quenching probe method over other PCR-based methods for detection of the JAK2 V617F mutation.

@ Polymerase chain reaction detection of rearranged immunoglobulin heavy chain DNA in plasma samples is useful in the diagnosis of B-cell lymphoma.

 

i‚Rj×‹ÛEƒEƒCƒ‹ƒXŠ´õ‚ÆŽíX‚ÌŽ¾Š³‚Æ‚ÌŠÖ‚íè‚̉ðÍAŠ´õÇ‚̈â“`ŽqŒŸ¸–@

 

@‹ß”NAƒEƒCƒ‹ƒXŠ´õ‚ƁAŽíX‚ÌŽ¾Š³‚Ì”­Ç‚â•a‘ÔŒ`¬‚É‚¨‚¯‚é–ðŠ„‚Æ‚ÌŠÖ˜A‚ª·‚ñ‚ÉŒ¤‹†‚³‚ê‚Ä‚¢‚éB‚í‚ê‚í‚ê‚͗Տ°ŒŸ‘Ì‚ð—p‚¢‚āAEBƒEƒCƒ‹ƒX‚âƒwƒ‹ƒyƒXƒEƒCƒ‹ƒXŠ´õ‚ƃŠƒ“ƒp‘B«Ž¾Š³‚Æ‚ÌŠÖ˜A‚ÌŒ¤‹†‚ðs‚Á‚Ä‚¢‚éB‚Ü‚½AƒsƒƒŠ‹ÛŠ´õ‚ÆŽ©ŒÈ–Ɖu«Ž¾Š³‚Ì”­Ç‚Æ‚ÌŠÖ˜A‚ɂ‚¢‚Ä‚à‰ðÍ‚µ‚Ä‚¢‚éB

 

m“–Œ¤‹†Žº‚̏ã‹L‚ÉŠÖ‚·‚éÅ‹ß‚̘_•¶n

@ Catheter-related bloodstream infection by Tsukamurella inchonensis in an immunocompromised patient.

@ First report of sepsis caused by Rhodococcus corynebacterioides in a patient with myelodysplastic syndrome.

@ Human herpesvirus 8 DNA in HIV-negative Japanese patients with multicentric Castleman's disease and related diseases.

@ Resolution of refractory idiopathic thrombocytopenic purpura after eradication of Helicobactor pyroli.

 

i‚SjÇ—á‚̍זE•ªŽq¶•¨Šw“I‰ðÍ

 

@Žîᇐ«Ž¾Š³‚𒆐S‚Æ‚·‚é—Տ°Ç—á‚ɂ‚¢‚āA‚»‚ÌŽîᇍזE‚Ì“Á«‚ðA×–E”|—{AõF‘̉ðÍADNAERNA‚ÌðÍA×–E•\–Ê‚¨‚æ‚эזE“à’`”’‚̉ðÍ‚È‚Ç‚É‚æ‚èÚ×‚ɉðÍ‚µAÇ—á•ñ‚ðs‚Á‚Ä‚¢‚éB

 

m“–Œ¤‹†Žº‚̏ã‹L‚ÉŠÖ‚·‚éÅ‹ß‚̘_•¶n

@@A case of gray platelet syndrome masked by immune thrombocytopenia at presentation.

–Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case.

@ An autopsy case of multicentric Castleman's disease associated with interstitial nephritis and secondary AA amyloidosis.

 

i‚Tj×–EŠ”‚ÌŽ÷—§

 

@—Տ°ŒŸ‘Ì‚©‚番—£‚µ‚½ŽîᇍזE‚ð”|—{‚µ‚āA‚±‚ê‚Ü‚Å‚SŽí—ނ̃qƒg”’ŒŒ•aEƒŠƒ“ƒpŽî×–EŠ”‚ðŽ÷—§‚µ‚½B‚±‚ê‚ç‚́A‚»‚ÌŽ¾Š³‚̍זEƒ‚ƒfƒ‹‚Æ‚µ‚ÄŒ¤‹†‚É—p‚¢‚Ä‚¢‚éB

 

m“–Œ¤‹†Žº‚̏ã‹L‚ÉŠÖ‚·‚éÅ‹ß‚̘_•¶n

@ Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors.

@ A novel cell line derived from de novo acute myeloblastic leukaemia with trilineage myelodysplasia which proliferates in response to a Notch ligand, Delta-1 protein.

@ Establishment of a double Philadelphia chromosome-positive acute lymphoblastic leukemia-derived cell line.

 

y“–Œ¤‹†Žº‚̃ƒ“ƒo[z

 

y‹³ˆõz

 

‹³Žö@@“Œ“c C“ñ

•‹³@@ˆÉ“¡ ^ˆÈ

 

yÝÐ’†‚Ì‘åŠw‰@¶z

 

”ŽŽm‰Û’ö@‚R–¼

CŽm‰Û’ö@‚P–¼

 

 

yŽÀŒ±Žº‚Ì•—Œiz

:mlab_graduate-school.files:image004.jpg

 

y2012”N12ŒŽ@—Տ°ŒŸ¸ˆãŠw‰ï @ ‹ž“s:@‘Sˆõ‚Ì”­•\‚ªI‚í‚èA“’—t—¿—‚Ì‘Å‚¿ã‚°‰ï‚ɏo”­Iz

 

Macintosh HD:Users:stmlab:Desktop:image006.jpg

 

y2013”N12ŒŽ@ƒAƒƒŠƒJŒŒ‰tŠw‰ï @ ƒjƒ…[ƒI[ƒŠƒ“ƒYF Notchƒlƒ^‚âHIFƒlƒ^‚Ì”­•\‚ªI‚í‚èAƒIƒCƒXƒ^[‚̃ŒƒXƒgƒ‰ƒ“‚ցz

 

mlab_graduate-school.files/image010.gif

mlab_graduate-school.files/image011.gif

 

 

y2014”N11ŒŽ@—Տ°ŒŸ¸ˆãŠw‰ï @ •Ÿ‰ªF Œû‰‰‚ªI‚í‚èA…‚½‚«—¿’à‚ցz

:mlab_graduate-school.files:image014.jpg

 

y2015”N11ŒŽ@—Տ°ŒŸ¸ˆãŠw‰ï @ Šò•ŒF –é’x‚­‚È‚èA‰wƒrƒ‹‚Ì’èH‰®‚Å‘Å‚¿ã‚°‚ð‚µ‚½‚½‚߁AŽü‚è‚Ì–À˜f‚É‚È‚é‚̂Ŏʐ^‚ÍŽB‚ç‚È‚©‚Á‚½z

@‚È‚µ

 

y2016”N3ŒŽ@Asian Society for Clinical Pathology and Laboratory Medicine Congress @ Taipeiz

 

mlab_graduate-school.files/image016.gif

 

y2016”N9ŒŽ@—Տ°ŒŸ¸ˆãŠw‰ï @ _ŒËF Œû‰‰‚ªI‚í‚èA_ŒË‹‚ðH‚׏I‚í‚Á‚½‚Æ‚±‚ëz

mlab_graduate-school.files/image017.gif

 

y2016”N12ŒŽ@ƒAƒƒŠƒJŒŒ‰tŠw‰ï @ San DiegoF MYD88ƒlƒ^‚Ì”­•\‚𖳎–I—¹z

 

../../Desktop/image%20020.gif

 

y2017”N8ŒŽ@Experimental HematologyŠw‰ï @ ƒhƒCƒcEƒtƒ‰ƒ“ƒNƒtƒ‹ƒg‘åŠwz

 

../../Desktop/image016.gif

 

y2017”N11ŒŽ@—Տ°ŒŸ¸ˆãŠw‰ï @ ‹ž“sFŒû‰‰‚ªI‚í‚èAŒü‚©‚¢‚̃vƒŠƒ“ƒXƒzƒeƒ‹‚Å‚¨’ƒz

 

../../Desktop/image021.gif

 

y2018”N11ŒŽ@—Տ°ŒŸ¸ˆãŠw‰ï @ VhF¬‚ñ‚Å‚¢‚½‚̂Ŏʐ^‚È‚µz

 

y2019”N6ŒŽ@ƒˆ[ƒƒbƒpŒŒ‰tŠw‰ï—ƒAƒ€ƒXƒeƒ‹ƒ_ƒ€:TYRO3ƒlƒ^‚̃|ƒXƒ^[”­•\‚̏€”õ’†z

 

::2019EHAŽÊ^2.jpg